Seroatlas · Human Serome Atlas

GZMM

Granzyme M

Also known as: GRAM_HUMAN, LMET1, MET1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P51124
Gene: GZMM
Ensembl: ENSG00000197540
Chromosome: 19
Canonical length: 257 aa
Protein class: Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
Secretome location: Secreted to blood

OverviewNCBI Gene

Human natural killer (NK) cells and activated lymphocytes express and store a distinct subset of neutral serine proteases together with proteoglycans and other immune effector molecules in large cytoplasmic granules. These serine proteases are collectively termed granzymes and include 4 distinct gene products: granzyme A, granzyme B, granzyme H, and the protein encoded by this gene, granzyme M. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]

Canonical amino-acid sequenceUniProt

257 residues, UniProt reviewed canonical sequence.

>P51124|GZMM
     1  MEACVSSLLV LALGALSVGS SFGTQIIGGR EVIPHSRPYM ASLQRNGSHL CGGVLVHPKW
    61  VLTAAHCLAQ RMAQLRLVLG LHTLDSPGLT FHIKAAIQHP RYKPVPALEN DLALLQLDGK
   121  VKPSRTIRPL ALPSKRQVVA AGTRCSMAGW GLTHQGGRLS RVLRELDLQV LDTRMCNNSR
   181  FWNGSLSPSM VCLAADSKDQ APCKGDSGGP LVCGKGRVLA RVLSFSSRVC TDIFKPPVAT
   241  AVAPYVSWIR KVTGRSA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GZMM can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.3
Highest tissue expression: 22 nTPM

Expression across tissuesHPA

Tissue

spleen: 22 nTPM
bone marrow: 20 nTPM
lymph node: 18 nTPM
appendix: 9.4 nTPM
thymus: 8.1 nTPM
small intestine: 5.9 nTPM

Single-cell type

nk-cells: 210 nCPM
t-cells: 137 nCPM
respiratory ionocytes: 5.1 nCPM
innate lymphoid cells: 5 nCPM
oocytes: 4.6 nCPM
pdcs: 4.5 nCPM

Immune cell

gdT-cell: 585 nTPM
memory CD8 T-cell: 471 nTPM
naive CD8 T-cell: 380 nTPM
MAIT T-cell: 367 nTPM
total PBMC: 227 nTPM
NK-cell: 195 nTPM

Brain region

cerebellum: 7 nTPM
cerebral cortex: 2.5 nTPM
medulla oblongata: 1.9 nTPM
pons: 1.9 nTPM
white matter: 1.9 nTPM
thalamus: 1.8 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.2
gnomAD pLI: 0.01
gnomAD missense Z: -0.07
DepMap mean gene effect: -0.05
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GZMM as an antibody target. Whether an autoantibody or antibody against GZMM could matter depends on whether native GZMM is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GZMM is annotated as secreted, so native GZMM circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label GZMM as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...